This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Generex Biotechnology Corporation
Drug Names(s): Oral Insulin, Oralin, Oral Recosulin, buccal spray insulin
Description: Oral-lyn is an oral insulin formulation that is delivered directly into the mouth, where it is absorbed into the bloodstream through the buccal mucosa.
Deal Structure: Generex Biotechnology Corporation announced in June 2006 that it entered into contractual arrangements with Cardinal Health to manufacture clinical trial batches of Generex Oral-lyn.
Under the terms of the contract, Cardinal Health will formulate and fill clinical trial batches of the canisters at its manufacturing and analytical services facility. Additional terms of the agreement were not disclosed.
Partners: Cardinal Health Inc.
Generex Oral-lyn News
Additional information available to subscribers only: